Among 278 patients with HER2-positive advanced gastric or GEJ adenocarcinoma treated in first-line treatment, we screened 151 patients who have received a second-line treatment between May 2010 and December 2015 (Figure 1). This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.